意义未明或肾脏意义单克隆丙种球蛋白病与CKD患者肾衰竭及死亡风险的关联
该回顾性队列研究纳入2013至2018年1535例同时有CKD诊断和单克隆检测的患者,分为MGRS组59例(4%)、MGUS组648例(42%)和无单克隆丙种球蛋白病组828例(54%)。校正年龄、性别、eGFR、蛋白尿和Charlson合并症指数后,MGUS/MGRS状态与肾衰竭风险无显著关联,但MGRS与全因死亡风险显著升高相关。
要点
- CKD患者中MGUS占42%、MGRS占4%,无单克隆丙种球蛋白病占54%。
- 未校正分析中MGRS肾衰竭风险较高(HR 2.5),校正传统危险因素后不再显著(HR 0.9)。
- 校正后MGRS与全因死亡风险显著升高相关,MGUS与死亡无显著关联。
核心结论
- 校正传统危险因素后,MGUS/MGRS状态与CKD患者进展至肾衰竭风险无显著关联,但MGRS与无单克隆丙种球蛋白病患者相比与全因死亡风险升高显著相关。
研究设计与样本
- 2013至2018年开展的回顾性队列研究,纳入同时有CKD诊断和单克隆检测的患者1535例,分为MGRS组59例(4%)、MGUS组648例(42%)和无单克隆丙种球蛋白病组828例(54%)。
主要发现
- 未校正分析以死亡为竞争风险时,MGRS组较无单克隆丙种球蛋白病组肾衰竭风险升高(HR 2.5,95%CI 1.5至4.2),MGUS组无显著差异(HR 1.3,95%CI 0.97至1.6)。
- 多变量校正年龄、性别、eGFR、蛋白尿和Charlson合并症指数后,MGRS组进展至肾衰竭风险不再有统计学意义(HR 0.9,95%CI 0.5至1.8)。
- 校正后MGUS组较无单克隆丙种球蛋白病组肾衰竭风险亦无显著差异(HR 1.3,95%CI 0.95至1.6)。
- 完全校正模型中,MGRS与全因死亡风险显著相关,而MGUS与全因死亡无显著关联。
临床怎么用
- 在CKD患者中检出MGUS或MGRS时,校正传统肾脏病进展危险因素后,单克隆丙种球蛋白病状态本身与肾衰竭风险无显著独立关联。
- MGRS状态与全因死亡风险升高显著相关,提示对CKD合并MGRS患者需关注死亡风险评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the prognostic significance of monoclonal gammopathy of undetermined and renal significance (MGUS and MGRS) in patients with CKD. The objective of this study was to determine the clinical and kidney outcomes of patients with CKD with either MGUS or MGRS compared with those with CKD without MGUS or MGRS. METHODS: We conducted a retrospective cohort study from 2013 to 2018. Patients who had both CKD diagnosis and monoclonal testing were identified. Patients were divided into MGRS, MGUS, and no monoclonal gammopathy groups. Cumulative incidence functions and Cox proportional hazards regression were used to model time to event data and to evaluate the association between monoclonal gammopathy status and risk of kidney failure, with death treated as a competing risk. RESULTS: Among 1535 patients, 59 (4%) had MGRS, 648 (42%) had MGUS, and 828 (54%) had no monoclonal gammopathy. Unadjusted analysis showed that compared with no monoclonal gammopathy patients, patients with MGRS were at higher risk of kidney failure (hazard ratio [HR] [95% confidence interval]: 2.5 [1.5 to 4.2] but not patients with MGUS (HR [95% confidence interval]: 1.3 [0.97 to 1.6]), after taking death into account as a competing risk. However, in the multivariable analysis, after adjusting for age, sex, eGFR, proteinuria, and Charlson Comorbidity Index, the risk of progression to kidney failure (with death as competing risk) in the MGRS group was no longer statistically significant (HR: 0.9 [0.5 to 1.8]). The same was also true for the MGUS group compared with the group with no monoclonal gammopathy (HR: 1.3 [0.95 to 1.6]). When evaluating the association between MGUS/MGRS status and overall survival, MGRS was significantly associated with mortality in fully adjusted models compared with the group with no monoclonal gammopathy, while MGUS was not. CONCLUSIONS: After adjusting for traditional risk factors, MGUS/MGRS status was not associated with a greater risk of kidney failure, but MGRS was associated with a higher risk of mortality compared with patients with no monoclonal gammopathy.
引用
- Sy-Go JPT, Moubarak S, Vaughan LE, et al. Monoclonal Gammopathy and Its Association with Progression to Kidney Failure and Mortality in Patients with CKD. Clin J Am Soc Nephrol. 2023. PMID: 37948069. doi:10.2215/CJN.0000000000000358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。